Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Asset Impairment Charges (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2013
Impaired Long-Lived Assets Held and Used [Line Items]
Long-lived assets held-for-sale	$ 84	[1],[2]
Assets held for sale, impairment	64	[3]
Assets abandoned or demolished	0	[1]
Assets abandoned or demolished, impairment	41
Long-lived assets	84	[1]
Long-lived assets, impairment	105
Fair Value, Inputs, Level 1 [Member]
Impaired Long-Lived Assets Held and Used [Line Items]
Long-lived assets held-for-sale	0	[1],[3]
Assets abandoned or demolished	0	[1]
Long-lived assets	0	[4]
Fair Value, Inputs, Level 2 [Member]
Impaired Long-Lived Assets Held and Used [Line Items]
Long-lived assets held-for-sale	84	[1],[3]
Assets abandoned or demolished	0	[1]
Long-lived assets	84	[4]
Fair Value, Inputs, Level 3 [Member]
Impaired Long-Lived Assets Held and Used [Line Items]
Long-lived assets held-for-sale	0	[1],[3]
Assets abandoned or demolished	0	[1]
Long-lived assets	$ 0	[4]

[1] The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1C. Basis of Presentation and Significant Accounting Policies: Fair Value.

[2] From the beginning of our cost-reduction/productivity initiatives in 2005 through March 31, 2013, Employee termination costs represent the expected reduction of the workforce by approximately 62,000 employees, mainly in manufacturing and sales and research, of which approximately 54,000 employees have been terminated as of March 31, 2013. For the three months ended March 31, 2013, the credit to employee terminations reflects a change in estimate related to the number of employees to be terminated and the expected total cost of planned terminations.The restructuring charges for the three months ended March 31, 2013 are associated with the following:•Primary Care operating segment ($5 million income), Specialty Care and Oncology operating segment ($6 million), Established Products and Emerging Markets operating segment ($11 million), other operating segments ($2 million), research and development operations ($2 million), manufacturing operations ($4 million) and Corporate ($79 million).The restructuring charges for the three months ended April 1, 2012 are associated with the following:•Primary Care operating segment ($3 million), Specialty Care and Oncology operating segment ($3 million), Established Products and Emerging Markets operating segment ($3 million), other operating segments ($6 million), research and development operations ($12 million), manufacturing operations ($152 million) and Corporate ($318 million).

[3] Reflects property, plant and equipment and other long-lived held-for-sale assets written down to their fair value of $84 million, less costs to sell of $2 million (a net of $82 million), in the first three months of 2013. Fair value was determined primarily using a market approach, with various inputs, such as recent sales transactions.

[4] Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes.